Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › TN › Chattanooga › NPI 1619056462

Stephen V Dreskin MD PC

Stephen V Dreskin MD PC was paid $528K by Medicaid between Jan 2018 and Dec 2024, across 30 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.

33Billing provider infoSTEPHEN V DRESKIN MD PC
CHATTANOOGA, TN 37421
33aNPI1619056462assigned 11/03/2006
33bProvider typeSpecialist
28Total paid$528K
24GClaims67,861
24DCodes billed30
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Specialist providers in Tennessee

Rank by total paid#48 of 252
Median peer was paid$57K
This provider vs. median9.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$20K$40K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201816,345$244K
201910,694$50K
20207,684$25K
202110,334$46K
20229,252$54K
20238,310$51K
2024incomplete5,242$56K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 35% 32,908 23,036 $184K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 29% 18,784 12,923 $156K
99203 Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity 12% 2,071 1,671 $62K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 9.6% 2,231 1,923 $51K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3.7% 3,757 3,202 $20K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 3.6% 3,127 2,600 $19K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 3.1% 419 325 $16K
80305 2.2% 3,533 2,781 $12K
L0648 Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf <1% 22 13 $4K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 56 56 $2K
81025 <1% 207 192 $735.40
64493 <1% 43 27 $727.30
18 more codes
99442 <1% 40 $550.27
64483 <1% 25 $500.05
64494 <1% 43 $417.69
64484 <1% 26 $242.03
81226 <1% 50 $88.74
81225 <1% 50 $57.34
81227 <1% 37 $34.40
81241 <1% 50 $14.85
81291 <1% 50 $12.00
81355 <1% 50 $8.00
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 17 $6.91
99000 0% 42 $0.00
81231 0% 37 $0.00
81240 0% 50 $0.00
81230 0% 37 $0.00
81401 0% 25 $0.00
81328 0% 37 $0.00
81479 Unlisted molecular pathology procedure 0% 37 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGENTER, AMBER (MANAGER)